FICTIONAL DOCUMENT-REVIEW EXERCISE — NOT AN AUTHENTIC RECORD
All people, organizations, identifiers, legal conclusions, clinical parameters,
and events are invented for text retrieval practice. Do not use as professional
advice, an authoritative standard, a real filing, or an operational instruction.

RECORD 4: INVENTOR INTERVIEW & PATENT COUNSEL LEGAL MEMORANDUM
Document ID: NVEL-MEMO-2026-PAT-03
Author: Jonathan Hayes, Registered Patent Attorney (USPTO Reg. No. 64,812)
Date: 2026-08-14
Subject: 35 U.S.C. § 102 / § 103 Novelty & Obviousness Clearance Opinion

1. STATUTORY 102 NOVELTY CLEARANCE
1.1 Reference A (FICTIONAL REFERENCE A) anticipates neither Claim 1 nor Claim 2: It teaches single-element Ta doping only (y = 0.2 to 0.6) and expressly lacks scandium (x = 0).
1.2 Reference B (FICTIONAL REFERENCE B) does not anticipate: It teaches single-element Sc doping only, with an ionic conductivity ceiling of 0.68 mS/cm, failing the 1.70 mS/cm threshold.
1.3 Conclusion: Independent Claim 1 is strictly novel under 35 U.S.C. § 102.

2. STATUTORY 103 OBVIOUSNESS ANALYSIS & UNEXPECTED RESULTS
2.1 A prima facie obviousness rejection combining Ref A and Ref B is overcome by:
  a. Reference A's express teaching away regarding trivalent cation additions causing detrimental LaScO3 secondary phases.
  b. Synergy / Unexpected Results: Synergistic co-doping of Sc (trivalent) and Ta (pentavalent) achieves 1.85 mS/cm, which is 81% higher than Ref A (1.02 mS/cm) and 172% higher than Ref B (0.68 mS/cm).
2.2 Confidentiality Warning: The draft provisional claims and experimental synthesis conditions have not been publicly disclosed. Any upload to public or commercial AI services risks creating an effective public disclosure bar under 35 U.S.C. § 102(a)(1) or triggering absolute novelty loss under European Patent Convention (EPC) Article 54.